Skip to content

US · VNDA · BIOTECHNOLOGY

Vanda Pharmaceuticals Inc. (VNDA) intrinsic value and stock valuation

$3.45as of 2026-11-21 · Mkt cap 306.09M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vanda Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values VNDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VNDA’s statements →

Vanda Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Washington, DC 20037 vandapharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$216.1M-2.7% 5y CAGRd
20112025
Net income
-$-220.47M
20112025
Free cash flow
-$-110.44M
20112025
Total equity
$327.2M-6.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$216.1M$198.8M$192.6M$254.4M$268.7M
Operating income-$-151.17M-$-40.66M-$-13.95M$6.33M$42.2M
Net income-$-220.47M-$-18.9M$2.51M$6.28M$33.2M
EPSd-$-3.74M-$-325.02K$43.6K$110.2K$582.4K
Operating cash flow-$-109.44M-$-15.76M$12.8M$32M$64.2M
Capital expenditure-$-1M-$-490K-$-380K-$-680K-$-550K
Free cash flow-$-110.44M-$-16.25M$12.4M$31.3M$63.7M
Total assets$489M$656.2M$648.4M$634.3M$593.8M
Total debt$12.6M$12.4M$9.4M$11.1M$12.4M
Net debt-$-72.23M-$-89.96M-$-126.42M-$-123.89M-$-39.7M
Total equity$327.2M$538.6M$544.9M$527.2M$504.9M
Cash and short-term investments$263.9M$374.6M$388.3M$466.9M$432.8M
Income statement
20252024202320222021
Revenue$216.1M$198.8M$192.6M$254.4M$268.7M
Cost of revenue$13M$11.3M$14.8M$24.3M$25.6M
Gross profit$203.1M$187.5M$177.8M$230.1M$243.1M
Research and development expenses$109.3M$74.4M$76.8M$85.8M$75.4M
Selling, general and administrative expenses$238M$146.4M$112.9M$136.5M$124.1M
Other expenses$7.01M$7.27M$2.09M$1.52M$1.48M
Operating expenses$354.2M$228.1M$191.8M$223.8M$200.9M
Cost and expenses$367.3M$239.4M$206.6M$248.1M$226.5M
Interest income$0.00$0.00$0.00$0.00$200K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$11.9M$8.13M$3.01M$2.73M$2.84M
Ebitda-$-126.73M-$-14.79M$9.35M$14M$45.2M
Operating income-$-151.17M-$-40.66M-$-13.95M$6.33M$42.2M
Total other income/expenses, net$12.5M$17.7M$20.3M$4.97M$200K
Income before tax-$-138.65M-$-22.92M$6.34M$11.3M$42.4M
Income tax expense$81.8M-$-4.02M$3.83M$5.03M$9.21M
Net income-$-220.47M-$-18.9M$2.51M$6.28M$33.2M
Weighted average shares outstanding$58.9M$58.2M$57.4M$56.5M$55.6M
Weighted average diluted shares outstanding$58.9M$58.2M$57.6M$57M$56.9M
Balance sheet
20252024202320222021
Cash and short-term investments$263.9M$374.6M$388.3M$466.9M$432.8M
Net receivables$54.6M$47.1M$34.2M$33.5M$32.5M
Inventory$1.85M$1.73M$1.36M$1.19M$1.02M
Total current assets$347.3M$438.9M$433M$519.3M$478.3M
Property, plant and equipment, net$13.5M$12.7M$9.14M$11M$12.4M
Goodwill and intangible assets$117.1M$114.1M$121.4M$18.6M$20.1M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$141.7M$217.3M$215.5M$115M$115.5M
Total assets$489M$656.2M$648.4M$634.3M$593.8M
Accounts payable$4.94M$3.5M$7.14M$12.7M$930K
Short-term debt$5.55M$4.27M$2.4M$2.33M$2.31M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$145.2M$100M$87.7M$91.4M$74.4M
Long-term debt$7.07M$8.09M$7.01M$8.81M$10.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$16.6M$17.7M$15.8M$15.6M$14.5M
Capital lease obligations$12.6M$12.4M$9.4M$11.1M$12.4M
Total liabilities$161.8M$117.7M$103.5M$107.1M$88.9M
Common stock$60K$60K$60K$60K$60K
Retained earnings-$-394.77M-$-174.29M-$-155.39M-$-157.9M-$-164.18M
Accumulated other comprehensive income (loss)$630K$70K-$-30K-$-1.19M-$-170K
Total equity$327.2M$538.6M$544.9M$527.2M$504.9M
Total investments$179M$272.3M$252.4M$331.8M$380.7M
Total debt$12.6M$12.4M$9.4M$11.1M$12.4M
Net debt-$-72.23M-$-89.96M-$-126.42M-$-123.89M-$-39.7M
Cash flow statement
20252024202320222021
Net income-$-220.47M-$-18.9M$2.51M$6.28M$33.2M
Depreciation and amortization-$-950K$8.13M$3.01M$2.73M$2.84M
Stock-based compensation$9.47M$12.4M$14M$16.3M$15.4M
Change in working capital$8.31M-$-6.56M-$-750K$6.07M$2.74M
Accounts receivable-$-7.46M-$-13.01M-$-710K-$-1.09M-$-2.47M
Inventory-$-3.47M-$-30K-$-770K-$-4.48M-$-2.23M
Accounts payable$15.8M$1.71M-$-10.98M$11.8M$3.04M
Net cash provided by operating activities-$-109.44M-$-15.76M$12.8M$32M$64.2M
Investments in property, plant and equipment-$-1M-$-490K-$-380K-$-680K-$-550K
Acquisitions, net$0.00-$-4.23M-$-100.67M$0.00$0.00
Net cash used for investing activities$94.9M-$-17.43M-$-12.06M$49.9M-$-76.7M
Common stock issued$0.00$0.00$0.00$730K$3.55M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.91M-$-150K$0.00$730K$3.55M
Net change in cash-$-17.36M-$-33.51M$790K$83M-$-9.02M
Cash at end of period$85.3M$102.8M$136.3M$135M$52.1M
Operating cash flow-$-109.44M-$-15.76M$12.8M$32M$64.2M
Capital expenditure-$-1M-$-490K-$-380K-$-680K-$-550K
Free cash flow-$-110.44M-$-16.25M$12.4M$31.3M$63.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vanda Pharmaceuticals Inc.

        Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

        CEO
        Mihael H. Polymeropoulos
        Employees
        533
        Beta
        0.60

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Vanda Pharmaceuticals Inc. (VNDA)?

        Vanda Pharmaceuticals Inc. (VNDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VNDA undervalued?

        VNDA trades at a price of $3.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.